Ivermectine Substipharm

Ivermectin, the active ingredient in Ivermectine Substipharm, is a Anthelmintic presented as an oral dosage form for oral administration. It targets a variety of parasitic worm and ectoparasite infections, providing therapeutic benefit in affected individuals across age groups. It is indicated for several neglected tropical diseases and is included in WHO‑endorsed treatment guidelines.

GNH USA supplies Ivermectine Substipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for global health programs, including public health initiatives and private sector procurement.

Ivermectin is an antiparasitic agent used to treat infections caused by helminths and ectoparasites. - Onchocerciasis: reduces microfilarial load and helps prevent ocular complications. - Strongyloidiasis: eliminates intestinal larvae and prevents hyperinfection. - Scabies: eradicates Sarcoptes mites, relieving skin lesions. - Lymphatic filariasis: decreases microfilariae, contributing to transmission control. - Other helminth infections: provides broad‑spectrum activity against various nematodes.

Ivermectin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring shortly after dosing. - Itching: localized pruritus at the site of parasite die‑off.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neurologic events: including seizures, altered consciousness or visual disturbances.

When prescribing Ivermectine Substipharm, clinicians should observe several safety considerations. - Pregnancy: safety not established; avoid unless potential benefit outweighs risk. - Breastfeeding: unknown excretion in milk; consider risk versus benefit. - Renal impairment: use with caution and monitor plasma levels if severe. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Ivermectin can interact with other medicines that affect its metabolism or transport.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce ivermectin exposure. - Warfarin: concurrent use may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin, clarithromycin): can increase ivermectin plasma concentrations. - Azole antifungals (e.g., ketoconazole, itraconazole): may raise drug levels. - P‑glycoprotein inhibitors (e.g., verapamil, amiodarone): may modestly increase exposure.